Randomised controlled trials of antipsychotics for people with autism spectrum disorder: a systematic review and a meta-analysis
Authors:
- 4 August 2023
- journal article
- review article
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 53 (16) , 7964-7972
Abstract
Background: Despite unclear evidence to support the long-term use of antipsychotics to treat challenging (problem) behaviours in people with autism in the absence of a psychiatric disorder, this practice is common.Methods: We conducted a systematic review and meta-analysis of all randomised controlled trials (RCTs) involving antipsychotics for people with autism of all ages, irrespective of the outcomes assessed. We searched seven databases and hand-searched ten relevant journals. Two authors independently screened titles, abstracts and full papers and extracted data using the Cochrane Handbook template. We conducted meta-analyses of outcomes and the rate of adverse events.Results: We included 39 papers based on 21 primary RCTs that recruited 1482 people with autism. No RCT assessed any psychiatric disorder outcome, such as psychoses or bipolar disorder. A meta-analysis of ten placebo-controlled RCTs showed a significantly improved Aberrant Behaviour Checklist-Irritability score in the antipsychotic group with an effect size of −6.45 [95% confidence interval (CI) −8.13 to −4.77] (low certainty). Pooled Clinical Global Impression data on 11 placebo-controlled RCTs showed an overall effect size of 0.84 (95% CI 0.48 to 1.21) (moderate certainty). There was a significantly higher risk of overall adverse effects (p = 0.003) and also weight gain (p < 0.00001), sedation (p < 0.00001) and increased appetite (p = 0.001) in the antipsychotic group.Conclusions: There is some evidence for risperidone and preliminary evidence for aripiprazole to significantly improve scores on some outcome measures among children with autism but not adults or for any other antipsychotics. There is a definite increased risk of antipsychotic-related different adverse effects.Keywords
This publication has 28 references indexed in Scilit:
- Psychopharmacological treatment in children and adolescents with autism spectrum disorders in GermanyResearch in Developmental Disabilities, 2013
- GRADE guidelines: 12. Preparing Summary of Findings tables—binary outcomesJournal of Clinical Epidemiology, 2013
- Use of Psychotropic Medication in Children and Adolescents With Autism Spectrum DisordersPediatrics, 2012
- Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: A systematic reviewResearch in Developmental Disabilities, 2011
- The use of pure and impure placebo interventions in primary care - a qualitative approachBMC Family Practice, 2011
- Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic DisorderPediatrics, 2009
- Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental DisordersPediatrics, 2004
- Risperidone in Children with Autism and Serious Behavioral ProblemsNew England Journal of Medicine, 2002
- Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disordersJournal of Autism and Developmental Disorders, 1994
- Austism diagnostic observation schedule: A standardized observation of communicative and social behaviorJournal of Autism and Developmental Disorders, 1989